Olink® Proteomics Services
GENEWIZ Proteomics Services uses Olink® Proximity Extension™ Assay (PEA™) technology to optimize the detection and quantification of circulating proteins. Unlike traditional methods, this approach enables high-throughput, simultaneous analysis of proteins with high specificity and sensitivity using minimal sample amounts. As a Certified Service Provider (CSP) of Olink proteomics technology, we offer uniquely scalable solutions from high-plex Olink Explore HT and Reveal, to mid-plex Target 48 and 96 assays, down to customized Flex and Focus assays. Processing is available for research use only (RUO) or can be performed in our GCP-compliant CAP-accredited, CLIA-certified laboratory for clinical applications.
Proteomics, the study of proteins, provides a comprehensive picture of disease phenotypes and mechanisms at the functional site. Through proteomics at a population scale, scientists can identify causal proteins, uncover novel pathways, and discover potential therapeutic targets. This holistic approach has the potential to revolutionize drug development.
Is GENEWIZ an Olink Certified Services Provider?
As a Certified Service Provider (CSP) of Olink proteomics technology, we offer uniquely scalable solutions from high-plex Olink Explore HT and Reveal, to mid-plex Target 48 and 96 assays, down to customized Flex and Focus assays.
Olink Proteomics Panels
Olink platforms scale from high-plex (Explore HT, Reveal, and Explore 3072), to mid-plex (Target 48 and Target 96), down to customized low-plex assays (Focus and Flex).
| Olink Platform | Description | Details | Download |
|---|---|---|---|
| Explore HT | Containing over 5,400 proteins with proven specificity, Olink Explore HT offers 100% coverage of top-level pathways and is the next generation solution for high-throughput proteomics. | The most comprehensive panel yet, Explore HT includes 2,536 new biomarkers. With Olink Explore HT, just 2 µL of sample are consumed to measure over 5,300 proteins. Data are available via NPX values, or Normalized Protein Expression, for relative protein quantification. | Click to download the assay list: Explore HT Assay Protein Panels > |
| Reveal | With broad coverage, Olink Reveal is the most cost-effective panel yet. This accessible solution enables deep profiling of the proteome with as little as 4 μL of sample. |
|
Click to download the assay list: Reveal Protein Panels > |
| Target 96 | With Olink Target 96, choose from 15 strategically designed panels built for specific areas of human disease and key biological processes. For researchers working with mouse models, Target 96 Mouse Exploratory is also available. |
Disease areas:
Biological processes:
|
Click to download the assay list: Target 96 Protein Panels > |
| Target 48 | Olink Target 48 Cytokine and Immune Surveillance panels offer the highest relevance targets for investigating inflammatory processes, immune responses, and related diseases. These panels provide robust support for clinical trials and translational research. Target 48 Mouse Cytokine is also available. |
Use the Target 48 panels to elucidate:
|
Click to download the assay list:
Target 48 Cytokine Protein Panels >
Target 48 Immune Surveillance Protein Panels > |
| Flex & Focus | With Olink’s made-to-order products, Flex and Focus, researchers can select and combine 5-30 biomarkers into a single panel customized to fit their specific research needs. | Choose and combine pre-validated assays from Olink’s extensive biomarker library. The assays have 99% combinability and maintains the quality, performance, specificity, and sensitivity associated with standard Olink panels. The data is reported in absolute (pg/mL) or relative (NPX) quantification. | Click to download the assay list: Flex/Focus Protein Panels > |
Applications of Proteomics
-
Drug Target Identification & pQTLS
-
Biomarker Analysis & Screening
-
Patient Stratification
-
Predicting Drug Response
*Learn more about why researchers and clinicians include Olink Proteomics in their studies.
Olink Biomarker Detection Workflow
Deliverables
Standard Deliverables
- Absolute quantification in pg/ml (Olink Target 48 only)
- Data in Normalized Protein Expression (NPX) format for relative quantification
- Certificate of Analysis showing quality details – internal and external controls are included throughout the workflow to ensure data quality
Advanced Analysis
(In addition to standard deliverables)
- Data visualization: Provides a principal component analysis and heatmap to visualize sample distribution and protein expression – results are illustrated from differential expression analysis in both table and interactive-graphic formats
- Statistical analysis: Includes differentially expressed protein analysis – input will be absolute quantification value for Olink Target 48 or NPX value for Olink Target 96
Applications of Proteomics
-
Olink Certified Service Provider
Global CSP for Olink Explore HT, Reveal, Target, Flex and Focus assays
-
Sample and Material Management
Offering storage and transport of your samples
-
Fast Turnaround
Flexible turnaround times to suit your needs, whether you need expedited results or a more relaxed timeline
-
CAP and CLIA Processing
Processing available in our GCP- compliant CLIA and CAP laboratory for clinical applications
Features & Benefits
-
Uniquely scalable solutions with optional panel sizes and expandable multiomic solutions across DNA, RNA, Protein
-
Wide variety of sample types accepted, with as little as 1 µL needed for analysis (40 µL recommended for sample submission)
-
Dual-recognition of two antibodies and DNA barcoding unique to each protein with 99.5% of 5,400+ biomarkers displaying no cross-reactivity
-
Affordable proteomics solutions, with certified expertise and streamlined processing to reduce variability
-
Increased precision (average intra %CV <10% and inter %CV <20%) across multiplex and midplex assays
-
Dynamic range spanning more than 10 logs, which makes it ideal for the study of the plasma proteome
Technical Resources
-
Webinar │ Beyond the Genome: Revolutionizing Health with Population-Scale Proteomics and Biomarker Discovery
In this webinar, co-hosted with Olink, discover the role of proteomics in advancing personalized medicine. Our guest speaker, Haythem Latif, Ph.D., provides insights on the importance of biomarkers and how you can effectively integrate proteome data with large-scale genomic datasets to broaden your understanding of human health. Plus, learn about recent population-scale studies utilizing protein biomarker discovery to go beyond the genome.
-
Blog │ The Power of Proteomics
The landscape of drug development is constantly evolving, fueled by groundbreaking scientific advancements. While genetics has played a central role in understanding diseases, proteomics provides a more comprehensive picture of disease phenotypes and mechanisms. In this blog, discover how researchers and clinicians are using Olink proteomics to reshape the outcomes of their clinical studies.
-
Blog | Comparing Mass Spectrometry, ELISA, and Olink for Proteomics
The field of proteomics has evolved significantly in the last decade, with several technologies now available to assay protein biomarkers in clinical studies. In this article, we compare three popular approaches for proteomics – mass spectrometry, ELISA, and the Olink® Proximity Extension Assay (PEA) – and highlight their strengths and limitations.
-
White Paper │ Multiplex Analysis of Inflammatory Proteins: A Comparative Study Across Multiple Platforms
Multiplexing technologies are often challenged by cross-reactive binding or interference contributing to the signal readout, which can lead to poor specificity. Olink®‘s proprietary PEA technology circumvents these challenges by use of a dual recognition approach with matched pairs of antibodies labeled with complimentary DNA oligos. This white paper verifies the quality of Olink technology relative to two common multiplex proteomics platforms widely used in protein biomarker research.
-
Tech Note | Proteomic Biomarker Discovery to Support Clinical Trials
Traditionally preclinical exploratory research and clinical trial biomarker detection and measurement have been restricted to a few indicators measured by mass spectrometry and ELISA. Discover how GENEWIZ from Azenta has implemented fully validated protein biomarker discovery services using the Olink® Proximity Extension Assay (PEA) technology capable of detecting and measuring hundreds to thousands of proteins simultaneously.
-
Tech Note | High-Plex Exploratory Biomarker Discovery to Support Proteomics and Multiomics Research
The development of novel strategies for mid-to high-plex protein detection and quantification enables greater utilization of protein biomarkers across the drug discovery and development process. Using Olink® Proximity Extension Assay (PEA) technology, GENEWIZ has deployed fully validated protein biomarker discovery services for up to 1 million data points per experiment with comparable sensitivity to traditional methods and utilization of lower sample amounts.
-
Blog | How Olink Technology is Revolutionizing Proteomics and Multiomics
Current proteomics technologies often present limitations in terms of throughput, specificity, and cost. However, new innovations, such as Olink Proteomics’ PEA technology, are overcoming these challenges by enabling hundreds to thousands of proteins to be measured in a single sample. In this blog, discover how GENEWIZ from Azenta is leveraging PEA technology for protein biomarker discovery, its applications, and how it can complement genomics data to accelerate drug development.
-
Webinar | Precision Proteomics: How to Enable Biomarker Identification in Health and Disease
Hear directly from Olink Proteomics about precision protein analysis as a tool to improve health outcomes for patients with cancer, inflammatory, or age-related diseases. Take this chance to discover how you can bring your protein biomarker discovery to the next level with Olink PEA technology.
-
Webinar | Do More with Less: Harnessing the Power of Multiomics from a Single Sample
The -omics era has greatly expanded the repertoire of approaches available for researchers and clinicians to unravel the complexities underpinning human health. In this recording from the GENEWIZ Breakfast Talk at ASHG 2022, Dr. Andrea O’Hara presents a workflow to rapidly produce a diverse set of multiomics results, including genomics, epigenomics, transcriptomics, and proteomics, from a single blood draw.
-
Poster | A Demonstrated Workflow to Unleash the Multiomic Potential of a Single Blood Draw
The multiomics era has greatly expanded the repertoire of approaches available for researchers and clinicians to unravel the complexity underpinning human health. Explore how the GENEWIZ single blood draw multiomics workflow can drive more significant insights and innovation in human health applications.
NGS Platforms
For information on our NGS platforms as well as recommended configurations of your projects, please visit the NGS Platforms page. GENEWIZ does not guarantee data output or quality for sequencing-only projects.
